Needham & Company downgraded Pacira Pharmaceuticals (NASDAQ: PCRX) from Buy to Hold.Analyst Serge Belanger commented, "The FDA's briefing documents presaged ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Analyst Comments Downgrades

Pacira Pharmaceuticals (PCRX) PT Lowered to $36 at Goldman SachsFebruary 16, 2018 7:05 AM Pacira Pharma (PCRX): AdComm Votes 6:4 No for Nerve Block sNDA Approval, PT To $72 - WedbushFebruary 16, 2018 7:04 AM Pacira Pharmaceuticals (PCRX) PT Lowered to $32 at BMO CapitalFebruary 16, 2018 6:11 AM Pacira Pharmaceuticals (PCRX) PT Lowered to $40 at BarclaysFebruary 16, 2018 3:47 AM After-Hours Stock Movers 02/15: (SNCR) (TNDM) (MULE) Higher; (COHU) (ANET) (PCRX) Lower (more...)February 15, 2018 6:05 PM Pacira Pharma (PCRX) to Resume Trading at 4:15 pm ETFebruary 15, 2018 3:51 PM Pacira Pharma (PCRX) Confirms Only Four FDA Committee Members Voted to Recommend Approval of EXPAREL sNDAFebruary 15, 2018 3:36 PM Pacira Pharmaceuticals Statement on FDA Advisory Committee for EXPAREL® for Use as a Nerve Block to Produce Regional AnalgesiaFebruary 15, 2018 3:35 PM Pacira Pharmaceuticals Statement on FDA Advisory Committee for EXPAREL® for Use as a Nerve Block to Produce Regional AnalgesiaFebruary 15, 2018 3:34 PM Pacira Pharma (PCRX) Doesn't Win FDA Panel Backing of EXPAREL in 6 to 4 Vote Against Approval February 15, 2018 3:01 PM